中度至重度银屑病患者接受比美莫司单抗治疗的超级应答者概况：一项短期真实世界观察——IL PSO（意大利银屑病情况） - Suppr

Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis).

作者信息

Esposito Maria, Gisondi Paolo, Assorgi Chiara, Bellinato Francesco, Brianti Pina, Burlando Martina, Brunasso Giovanna, Caccavale Stefano, Caldarola Giacomo, Campione Elena, Calzavara Pinton Piergiacomo, Campanati Anna, Carrera Carlo Giovanni, Carugno Andrea, Cozzani Emanuele, Costanzo Antonio, Cusano Francesco, Dapavo Paolo, Dattola Annunziata, De Simone Clara, Di Caprio Roberta, Diotallevi Federico, Fargnoli Maria Concetta, Gaiani Francesca, Giunta Alessandro, Malagoli Piergiorgio, Marzano Angelo Valerio, Megna Matteo, Mercuri Santo Raffaele, Mortato Edoardo, Narcisi Alessandra, Orsini Diego, Potestio Luca, Quaglino Pietro, Richetta Antonio Giovanni, Romano Francesca, Sena Paolo, Vagnozzi Emanuele, Venturini Marina, Loconsole Francesco, Balato Anna

机构信息

Department of Biotechnological ad Applied Clinical Sciences, University of L'Aquila, via Vetoio-Coppito 2, 67100, L'Aquila, Italy.

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

出版信息

Clin Drug Investig. 2025 Jun;45(6):309-315. doi: 10.1007/s40261-025-01440-z. Epub 2025 May 15.

DOI:10.1007/s40261-025-01440-z

PMID:40372625

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12144061/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6521/12144061/4c30d41af68d/40261_2025_1440_Fig1_HTML.jpg

相似文献

Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis).

Clin Drug Investig. 2025 Jun;45(6):309-315. doi: 10.1007/s40261-025-01440-z. Epub 2025 May 15.

Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis).

Dermatol Ther (Heidelb). 2025 Jul;15(7):1797-1811. doi: 10.1007/s13555-025-01435-w. Epub 2025 May 13.

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).

Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023.

A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS).

J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e113-e116. doi: 10.1111/jdv.19464. Epub 2023 Aug 29.

Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).

Dermatol Pract Concept. 2024 Apr 1;14(2):e2024052. doi: 10.5826/dpc.1402a52.

Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).

J Dermatolog Treat. 2024 Dec;35(1):2393376. doi: 10.1080/09546634.2024.2393376. Epub 2024 Aug 20.

Effectiveness of long-term bimekizumab treatment and predictive factors for responders in moderate-to-severe psoriasis: A 52-week real-world study.

J Dermatol. 2025 Feb;52(2):317-328. doi: 10.1111/1346-8138.17532. Epub 2024 Nov 5.

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.

Dermatol Ther (Heidelb). 2022 Aug;12(8):1777-1792. doi: 10.1007/s13555-022-00760-8. Epub 2022 Jul 7.

The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis).

Clin Exp Dermatol. 2025 Mar 26;50(4):858-859. doi: 10.1093/ced/llae400.

Correction to: The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis).

Clin Exp Dermatol. 2025 Jun 25;50(7):1486. doi: 10.1093/ced/llaf175.

本文引用的文献

Effectiveness of long-term bimekizumab treatment and predictive factors for responders in moderate-to-severe psoriasis: A 52-week real-world study.

J Dermatol. 2025 Feb;52(2):317-328. doi: 10.1111/1346-8138.17532. Epub 2024 Nov 5.

Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24-week real-world study.

J Dermatol. 2024 Dec;51(12):1658-1664. doi: 10.1111/1346-8138.17427. Epub 2024 Aug 12.

Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced.

Clin Exp Dermatol. 2024 Sep 18;49(10):1186-1189. doi: 10.1093/ced/llae147.

Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).

Dermatol Pract Concept. 2024 Apr 1;14(2):e2024052. doi: 10.5826/dpc.1402a52.

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).

Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023.

Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.

Adv Ther. 2023 Mar;40(3):869-886. doi: 10.1007/s12325-022-02379-9. Epub 2022 Dec 14.

A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab.

J Cosmet Dermatol. 2023 Mar;22(3):1146-1148. doi: 10.1111/jocd.15543. Epub 2022 Nov 29.

Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report.

Dermatol Ther. 2022 Dec;35(12):e15952. doi: 10.1111/dth.15952. Epub 2022 Oct 28.

Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives.

Life (Basel). 2022 Sep 10;12(9):1412. doi: 10.3390/life12091412.

Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study.

J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1284-1291. doi: 10.1111/jdv.18126. Epub 2022 Apr 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis).

作者信息

机构信息

Department of Biotechnological ad Applied Clinical Sciences, University of L'Aquila, via Vetoio-Coppito 2, 67100, L'Aquila, Italy.

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

出版信息

Clin Drug Investig. 2025 Jun;45(6):309-315. doi: 10.1007/s40261-025-01440-z. Epub 2025 May 15.

DOI:10.1007/s40261-025-01440-z

PMID:40372625

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12144061/

Abstract

摘要

Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis).

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis).

作者信息

机构信息

出版信息

相似文献

本文引用的文献